New nasal spray for brain diseases passes first safety check in healthy volunteers
NCT ID NCT07050316
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety and tolerability of a new nasal spray called CBT101 in 48 healthy men. Participants received either a single dose or multiple doses over several days. The study did not aim to treat any disease, but to gather initial safety data before testing in patients with neurologic conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CBT101 (nasal spray)
What this could lead to
If safe, this could pave the way for future studies of CBT101 as a potential treatment for neurologic conditions.
What could go wrong
This is a very early Phase 1 trial in only 48 healthy men, so it cannot show whether CBT101 works for any disease. The main goal is safety, not effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROLOGIC DISEASES, GENERAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Eurofins Optimed
Gières, 38610, France